AlzeCure gets abstract on the NeuroRestore platform against Alzheimer's accepted for poster presentation at CTAD

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has received a second abstract approved for poster presentation at the annual Alzheimer's conference CTAD, Clinical Trials in Alzheimer's Disease, which this year will be held completely digitally on November 4-7.

The abstract titled ACD856, a novel cognitive enhancer targeting neurotrophin signaling for the treatment of Alzheimer’s Disease shows that AlzeCure’s leading drug candidate, ACD856, in the company's NeuroRestore platform has the potential for widespread use of various types of cognitive memory disorders. The abstract is based on the results that led to the selection of a drug candidate and the recent completion of a successful clinical microdose study; a work carried out in collaboration with Professor Bengt Winblad and Professor Maria Eriksdotter at Karolinska Institutet, as well as Pontus Forsell, Johan Sandin and Gunnar Nordvall at AlzeCure.

”It is very satisfactory that we have now received two abstracts approved for presentation at this leading Alzheimer's conference. The results we have seen, and which are summarized in this abstract, show the possibilities with our main candidate ACD856 and support further clinical studies. I am very much looking forward to our upcoming clinical studies with the candidate, which we expect to be able to start before the end of the year", said Martin Jönsson, CEO of AlzeCure Pharma AB.

The abstract and the poster will be available to registered participants online on CTAD's website from November 4, 2020.